Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: SWOG S0919: A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia

 


SWOG S0919: A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia


Trial Focus

Leukemia/Myelodysplasia

Objective

         This is a clinical trial of Idarubicin and Ara-C that will be administered by IV which is standard of care and Pravastatin that will be administered by mouth and is investigational.

IRB Protocol #

11-0765

Trial Status

OPEN

Principle Investigator

DAN POLLYEA

Sponsor

SWOG

Contact

EMILY DENONCOURT at (303)748-0566 or EMILY.DENONCOURT@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last up to 5 years. A follow up period will consist of clinic visits. // Eligibility criteria include but are not limited to 18 years or older with acute myelogenous leukemia.Eligibility criteria include but are not limited to 18 years or older with acute myelogenous leukemia.